grant
Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy
Organization UNIVERSITY OF TX MD ANDERSON CAN CTRLocation HOUSTON, UNITED STATESPosted 1 Aug 2024Deadline 31 Jul 2029
NIHUS FederalResearch GrantFY2025AdjuvantAdjuvant ChemotherapyAdjuvant Drug TherapyAntitumor ResponseB blood cellsB cellB cell tumorB cellsB-Cell ActivationB-Cell DevelopmentB-Cell Lymphocytic NeoplasmB-Cell NeoplasmB-CellsB-LymphocytesB-cellB-cell receptor repertoire sequencingB-cell receptor sequencingB-lineage tumorB7-H1BCR repertoire sequencingBCR seqBCR sequencingBCRseqBlood SampleBlood specimenBody TissuesBypassCD274CD8CD8BCD8B1CD8B1 geneCancer PatientCell BodyCell CommunicationCell FractionCell InteractionCell LineageCell-to-Cell InteractionCellsCheckpoint inhibitorClinical TrialsClinical effectivenessClonal ExpansionCombined Modality TherapyCoupledDNA mutationDiseaseDisorderDistantEctopic lymphoid organEctopic lymphoid structureFamilyFrequenciesGene TranscriptionGenesGeneticGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGoalsHumanIMiDImmuneImmune checkpoint inhibitorImmune mediated therapyImmune modulatory therapeuticImmunesImmuno-ChemotherapyImmunochemotherapyImmunogenomicsImmunologically Directed TherapyImmunotherapeutic agentImmunotherapyIn complete remissionInduction TherapyInferiorInfiltrationKeytrudaLYT3LeadLungLung ParenchymaLung Respiratory SystemLung TissueLymphatic cellLymphocyteLymphocyticMalignant Tumor of the LungMalignant neoplasm of lungMapsMediatingMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsModelingModern ManMultimodal TherapyMultimodal TreatmentMurineMusMutationNEOADJNSCLCNSCLC - Non-Small Cell Lung CancerNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNeoplasm MetastasisNivolumabNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaOpdivoOrganization ChartsPD-L1PDL-1PathologicPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPb elementPerioperativePhasePhenotypePilot ProjectsPopulationPre-Clinical ModelPreclinical ModelsPrediction of Response to TherapyPrimary NeoplasmPrimary TumorProgrammed Cell Death 1 Ligand 1Programmed Death Ligand 1ProteomicsPublic HealthPulmonary CancerPulmonary malignant NeoplasmRNA ExpressionRandomizedRelapseReportingResectableResectedResistanceRoleSamplingSecondary NeoplasmSecondary TumorSingle cell seqStructure of parenchyma of lungT memory cellT-CellsT-LymphocyteTechnologyTertiary lymphoid structureTestingTissuesTranscriptionTreatment EfficacyTreatment outcomeactivated B cellsanti-tumor responsearmbiomarker validationcancer metastasischeck point immunotherapycheck point inhibitor therapycheck point inhibitory therapycheck point therapycheckpoint immunotherapycheckpoint inhibitor therapycheckpoint inhibitory therapycheckpoint therapychemo-immuno therapychemoimmunotherapychemotherapyclinical practicecohortcombination therapycombined modality treatmentcombined treatmentcomplete responsecytotoxiccytotoxic CD8 T cellscytotoxic CD8 T lymphocyteeffective therapyeffective treatmentexperiencegenome mutationheavy metal Pbheavy metal leadimmune check point inhibitorimmune check point therapyimmune checkpoint therapyimmune drugsimmune microenvironmentimmune modulating agentsimmune modulating drugimmune modulating therapeuticsimmune modulatory agentsimmune modulatory drugsimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic therapeuticsimmunomodulating agentsimmunomodulating drugsimmunomodulator agentimmunomodulator drugimmunomodulator medicationimmunomodulator prodrugimmunomodulator therapeuticimmunomodulatory agentsimmunomodulatory drugsimmunomodulatory therapeuticsimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentimmunotherapeuticsimmunotherapy agentimprovedimproved outcomeinduction therapiesinsightintervention efficacylung cancerlymph cellmarker validationmemory T lymphocytemouse modelmulti-modal therapymulti-modal treatmentmulti-modalitymultimodalitymurine modelnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyorganizational structurepatient oriented outcomespatient populationpembrolizumabpersonalized immunotherapyphase 2 trialphase II trialpilot studypre-clinicalprecision immunotherapypreclinicalpredict therapeutic responsepredict therapy responsepreventpreventingprogrammed cell death ligand 1programmed cell death protein ligand 1programsprotein death-ligand 1randomisationrandomizationrandomly assignedresistance to therapyresistantresistant to therapyresponseresponse to therapyresponse to treatmentscRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell next generation sequencingsingle cell sequencingsingle cell transcriptomic profilingsingle-cell RNA sequencingsocial rolespatial RNA sequencingspatial gene expression analysisspatial gene expression profilingspatial multiomicsspatial omicsspatial resolved transcriptome sequencingspatial transcriptome analysisspatial transcriptome profilingspatial transcriptome sequencingspatial transcriptomicsspatial tri-omicsspatially resolved transcriptomicsspatio transcriptomicsstandard of caresurvival outcometertiary lymphoid organtherapeutic efficacytherapeutic resistancetherapeutic responsetherapy efficacytherapy predictiontherapy resistanttherapy responsethymus derived lymphocytetreatment predictiontreatment resistancetreatment responsetreatment response predictiontreatment responsivenesstreatment strategytumortumor cell metastasistumor immune microenvironmenttumor-immune system interactions
Description preview
PROJECT SUMMARY
Neoadjuvant and perioperative chemoimmunotherapy are the standard of care for the treatment of patients with
resectable non-small cell lung cancer (NSCLC). Unfortunately, the majority of patients with resectable NSCLC
do not benefit from neoadjuvant/perioperative immune checkpoint inhibitor (ICI)-based therapies for reasons
that…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click